Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 8/20 | 0.36 |
| ▸ | PPARG | P37231 | 5/20 | 0.36 |
| ▸ | PPARA | Q07869 | 5/20 | 0.36 |
| ▸ | ATP4A | P20648 | 2/20 | 0.36 |
| ▸ | ATP4B | P51164 | 2/20 | 0.36 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4591252 | 0.91 | ATP4A (0.37) | ERBB2MINK1PPARDATP4AATP4B | |
| SCHEMBL4600598 | 0.89 | ATP4A (0.37) | ATP4AATP4BFFAR1MAPT | |
| SCHEMBL4600322 | 0.86 | ERBB2 (0.56) | ERBB2MINK1PPARDPPARGPPARA | |
| SCHEMBL4591317 | 0.86 | ERBB2 (0.43) | ERBB2MINK1PPARDPPARGPPARA | |
| SCHEMBL4598672 | 0.83 | ERBB2 (0.41) | ERBB2MINK1PPARDPPARGPPARA | |
| SCHEMBL4599445 | 0.83 | ERBB2 (0.41) | ERBB2MINK1PPARDPPARGPPARA | |
| SCHEMBL4600061 | 0.80 | ERBB2 (0.45) | ERBB2MINK1PPARDPPARGPPARA | |
| SCHEMBL4602065 | 0.78 | ERBB2 (0.46) | ERBB2MINK1PPARDATP4AATP4B | |
| SCHEMBL4599925 | 0.77 | ERBB2 (0.50) | ERBB2MINK1ATP4AATP4BHMOX1 | |
| SCHEMBL4599664 | 0.76 | ERBB2 (0.44) | ERBB2MINK1PPARDATP4AATP4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429605-B2 | Phenylpyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-30 | — | — | US | claimed |
| EP-1912969-A1 | PHENYLPYRIDINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-04-23 | — | — | EP | claimed |
| WO-2007017169-A1 | PHENYLPYRIDINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-15 | — | — | WO | claimed |
| US-20070032530-A1 | Phenylpyridine derivatives | HOFFMANN-LA ROCHE INC. | 2007-02-08 | — | — | US | claimed |
| US-7429605-B2 | Phenylpyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-30 | — | — | US | disclosed |
| EP-1912969-A1 | PHENYLPYRIDINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007017169-A1 | PHENYLPYRIDINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032530-A1 | Phenylpyridine derivatives | HOFFMANN-LA ROCHE INC. | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032530-A1 | Phenylpyridine derivatives | CYP3A5, QDPR, DPYD | ERBB2 2010/4885MINK1 2493/4885PPARD 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.